Literature DB >> 20089873

Antipermeability function of PEDF involves blockade of the MAP kinase/GSK/beta-catenin signaling pathway and uPAR expression.

Jinling Yang1, Elia J Duh, Ruth B Caldwell, M Ali Behzadian.   

Abstract

PURPOSE: Pigment epithelium-derived factor (PEDF) is a potent inhibitor of vascular endothelial growth factor (VEGF)-induced endothelial permeability. The goal of this study was to understand the mechanism by which PEDF blocks VEGF-induced increases in vascular permeability.
METHODS: The paracellular permeability of bovine retinal endothelial (BRE) cells was measured by assaying transendothelial cell electrical resistance and tracer flux. Western blot analysis was used to show phosphorylation of VEGFR2, MAP kinases, and glycogen synthase kinase 3 (GSK3)-beta. Confocal imaging and Western blot analysis were used to determine subcellular distribution of beta-catenin. Real-time RT-PCR and Western blot analysis were used to quantify urokinase plasminogen activator receptor (uPAR) expression.
RESULTS: PEDF blocked VEGF-induced phosphorylation of extracellular signal-regulated kinase (ERK), p38 MAP kinase, the p38 substrate MAP kinase-activated protein kinase-2 (MAPKAPK-2), and GSK3-beta, but it had no effect on the phosphorylation of VEGFR2. In addition, the VEGF-induced transcriptional activation of beta-catenin and uPAR expression were blocked by PEDF and by inhibitors of p38 and MEK. Finally, the VEGF-induced increase in permeability was blocked by both PEDF and the same kinase inhibitors.
CONCLUSIONS: The data suggest that p38 MAP kinase and ERK act upstream of GSK/beta-catenin in VEGF-induced activation of the uPA/uPAR system and that PEDF-mediated inhibition of the VEGF-induced increase in vascular permeability involves blockade of this pathway. These findings are important for developing precise and potent therapies for treatment of diseases characterized by vascular barrier dysfunction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20089873      PMCID: PMC2891479          DOI: 10.1167/iovs.08-2878

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  44 in total

1.  Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for downregulation in hypoxia.

Authors:  Luigi Notari; Amanda Miller; Alfredo Martínez; Juan Amaral; Meihua Ju; Gregory Robinson; Lois E H Smith; S Patricia Becerra
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-08       Impact factor: 4.799

2.  Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer.

Authors:  Stephanie Filleur; Karl Volz; Thomas Nelius; Yelena Mirochnik; Hanhua Huang; Tetiana A Zaichuk; Maria S Aymerich; Sofia P Becerra; Ronald Yap; Dorina Veliceasa; Emelyn H Shroff; Olga V Volpert
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

3.  Cdc42Hs, but not Rac1, inhibits serum-stimulated cell cycle progression at G1/S through a mechanism requiring p38/RK.

Authors:  A Molnár; A M Theodoras; L I Zon; J M Kyriakis
Journal:  J Biol Chem       Date:  1997-05-16       Impact factor: 5.157

4.  beta-catenin is a target for the ubiquitin-proteasome pathway.

Authors:  H Aberle; A Bauer; J Stappert; A Kispert; R Kemler
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

5.  Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.

Authors:  J N Lavoie; G L'Allemain; A Brunet; R Müller; J Pouysségur
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

6.  p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells.

Authors:  S Rousseau; F Houle; J Landry; J Huot
Journal:  Oncogene       Date:  1997-10       Impact factor: 9.867

7.  MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor.

Authors:  Y Yu; J D Sato
Journal:  J Cell Physiol       Date:  1999-02       Impact factor: 6.384

8.  Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas.

Authors:  B Mann; M Gelos; A Siedow; M L Hanski; A Gratchev; M Ilyas; W F Bodmer; M P Moyer; E O Riecken; H J Buhr; C Hanski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  p38 Mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression.

Authors:  Jianqiang Yu; Dafang Bian; Chitladda Mahanivong; Robert K Cheng; Wenyun Zhou; Shuang Huang
Journal:  J Biol Chem       Date:  2004-09-14       Impact factor: 5.157

10.  p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis.

Authors:  Taro Matsumoto; Ingela Turesson; Majlis Book; Pär Gerwins; Lena Claesson-Welsh
Journal:  J Cell Biol       Date:  2002-01-07       Impact factor: 10.539

View more
  21 in total

Review 1.  Pigment epithelium-derived factor as an anticancer drug and new treatment methods following the discovery of its receptors: a patent perspective.

Authors:  Katrina B Manalo; Peter F M Choong; S Patricia Becerra; Crispin R Dass
Journal:  Expert Opin Ther Pat       Date:  2011-01-05       Impact factor: 6.674

2.  17β-estradiol and tamoxifen prevent gastric cancer by modulating leukocyte recruitment and oncogenic pathways in Helicobacter pylori-infected INS-GAS male mice.

Authors:  Alexander Sheh; Zhongming Ge; Nicola M A Parry; Sureshkumar Muthupalani; Julia E Rager; Arkadiusz R Raczynski; Melissa W Mobley; Amanda F McCabe; Rebecca C Fry; Timothy C Wang; James G Fox
Journal:  Cancer Prev Res (Phila)       Date:  2011-06-16

3.  Deletion of hemojuvelin, an iron-regulatory protein, in mice results in abnormal angiogenesis and vasculogenesis in retina along with reactive gliosis.

Authors:  Amany Tawfik; Jaya P Gnana-Prakasam; Sylvia B Smith; Vadivel Ganapathy
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-08       Impact factor: 4.799

Review 4.  The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential.

Authors:  S Patricia Becerra; Vicente Notario
Journal:  Nat Rev Cancer       Date:  2013-03-14       Impact factor: 60.716

5.  Inhibition of GSK3α/β promotes increased pulmonary endothelial permeability to albumin by reactive oxygen/nitrogen species.

Authors:  Paul Neumann; Hiba Alsaffar; Nancy Gertzberg; Arnold Johnson
Journal:  Pulm Pharmacol Ther       Date:  2013-06-11       Impact factor: 3.410

6.  Anti-angiogenic actions of the mangosteen polyphenolic xanthone derivative α-mangostin.

Authors:  Kanjana Jittiporn; Jutamas Suwanpradid; Chintan Patel; Modesto Rojas; Suwan Thirawarapan; Primchanien Moongkarndi; Wisuda Suvitayavat; Ruth B Caldwell
Journal:  Microvasc Res       Date:  2014-04-08       Impact factor: 3.514

7.  Potential therapeutic effects of pigment epithelium-derived factor for treatment of diabetic retinopathy.

Authors:  Xiao Liu; Hui-Hui Chen; Li-Wei Zhang
Journal:  Int J Ophthalmol       Date:  2013-04-18       Impact factor: 1.779

8.  Blockade of VEGF-induced GSK/β-catenin signaling, uPAR expression and increased permeability by dominant negative p38α.

Authors:  Jinling Yang; Ruth B Caldwell; M Ali Behzadian
Journal:  Exp Eye Res       Date:  2012-04-30       Impact factor: 3.467

9.  Alterations of retinal vasculature in cystathionine-Beta-synthase mutant mice, a model of hyperhomocysteinemia.

Authors:  Amany Tawfik; Mohamed Al-Shabrawey; Penny Roon; Srinivas Sonne; Jason A Covar; Surapoon Matragoon; Preethi S Ganapathy; Sally S Atherton; Azza El-Remessy; Vadivel Ganapathy; Sylvia B Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

10.  Differential roles of uPAR in peritoneal ovarian carcinomatosis.

Authors:  Nada N Al-Hassan; Ali Behzadian; Ruth Caldwell; Vessela S Ivanova; Viqar Syed; Kouros Motamed; Neveen A Said
Journal:  Neoplasia       Date:  2012-04       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.